Acute Intermittent Porphyria Market Size
Market Size in USD Bn
CAGR6.3%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 6.3% |
| Market Concentration | High |
| Major Players | Alnylam Pharmaceuticals, Recordati Rare Diseases, Mitsubishi Tanabe Pharma, Dicerna Pharmaceuticals, Moderna and Among Others |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Acute Intermittent Porphyria Market Analysis
The acute intermittent porphyria market is estimated to be valued at USD 1.52 Billion in 2025 and is expected to reach USD 2.33 Billion by 2032, growing at a compound annual growth rate (CAGR) of 6.3% from 2025 to 2032. The market has been expanding in recent years due to the rising prevalence of acute intermittent porphyria worldwide. Factors such as growing awareness about the condition and its treatment options are supporting the growth of this market.